{"transactions":[{"id":4626158,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T20:29:33.000Z","date":"2026-09-23","kind":"sale","planned":false,"acquired":false,"shares":4528,"price":1.61,"value":7290.08,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.60 to $1.77 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001231919-26-001224","document":"form4-09242026_080923.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926001224/form4-09242026_080923.xml","form_type":"4"}},{"id":4626157,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T20:29:33.000Z","date":"2026-09-23","kind":"sale","planned":false,"acquired":false,"shares":114851,"price":1.61,"value":184910.11,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.60 to $1.77 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001231919-26-001224","document":"form4-09242026_080923.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926001224/form4-09242026_080923.xml","form_type":"4"}},{"id":4626156,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T20:29:33.000Z","date":"2026-09-22","kind":"sale","planned":false,"acquired":false,"shares":1088,"price":1.65,"value":1795.2,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":4528,"source":{"system":"sec-edgar","filing":"0001231919-26-001224","document":"form4-09242026_080923.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926001224/form4-09242026_080923.xml","form_type":"4"}},{"id":4626155,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T20:29:33.000Z","date":"2026-09-22","kind":"sale","planned":false,"acquired":false,"shares":27612,"price":1.65,"value":45559.8,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":114851,"source":{"system":"sec-edgar","filing":"0001231919-26-001224","document":"form4-09242026_080923.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926001224/form4-09242026_080923.xml","form_type":"4"}},{"id":4624123,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-18T22:37:58.000Z","date":"2026-09-16","kind":"sale","planned":false,"acquired":false,"shares":1285,"price":1.91,"value":2454.35,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 to $2.11 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":5616,"source":{"system":"sec-edgar","filing":"0001231919-26-001197","document":"form4-09182026_100949.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926001197/form4-09182026_100949.xml","form_type":"4"}},{"id":4624122,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-18T22:37:58.000Z","date":"2026-09-16","kind":"sale","planned":false,"acquired":false,"shares":32607,"price":1.91,"value":62279.37,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 to $2.11 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":142463,"source":{"system":"sec-edgar","filing":"0001231919-26-001197","document":"form4-09182026_100949.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926001197/form4-09182026_100949.xml","form_type":"4"}},{"id":680029,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:57:08.000Z","date":"2026-08-20","kind":"sale","planned":false,"acquired":false,"shares":6495,"price":0.32,"value":2078.4,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":7850155,"source":{"system":"sec-edgar","filing":"0001231919-26-000959","document":"form4-08202026_090856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926000959/form4-08202026_090856.xml","form_type":"4"}},{"id":680028,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:57:08.000Z","date":"2026-08-20","kind":"sale","planned":false,"acquired":false,"shares":46,"price":0.32,"value":14.72,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":55208,"source":{"system":"sec-edgar","filing":"0001231919-26-000959","document":"form4-08202026_090856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926000959/form4-08202026_090856.xml","form_type":"4"}},{"id":680027,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:57:08.000Z","date":"2026-08-20","kind":"sale","planned":false,"acquired":false,"shares":1159,"price":0.32,"value":370.88,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":1400560,"source":{"system":"sec-edgar","filing":"0001231919-26-000959","document":"form4-08202026_090856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926000959/form4-08202026_090856.xml","form_type":"4"}},{"id":680026,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:57:08.000Z","date":"2026-08-19","kind":"sale","planned":false,"acquired":false,"shares":57476,"price":0.35,"value":20116.6,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.33 to $0.36 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":7856650,"source":{"system":"sec-edgar","filing":"0001231919-26-000959","document":"form4-08202026_090856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926000959/form4-08202026_090856.xml","form_type":"4"}},{"id":680025,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:57:08.000Z","date":"2026-08-19","kind":"sale","planned":false,"acquired":false,"shares":409,"price":0.35,"value":143.15,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.33 to $0.36 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":55254,"source":{"system":"sec-edgar","filing":"0001231919-26-000959","document":"form4-08202026_090856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926000959/form4-08202026_090856.xml","form_type":"4"}},{"id":680024,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:57:08.000Z","date":"2026-08-19","kind":"sale","planned":false,"acquired":false,"shares":10255,"price":0.35,"value":3589.25,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.33 to $0.36 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":1401719,"source":{"system":"sec-edgar","filing":"0001231919-26-000959","document":"form4-08202026_090856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926000959/form4-08202026_090856.xml","form_type":"4"}},{"id":680023,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:57:08.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":253080,"price":0.38,"value":96170.4,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35 to $0.41 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":7914126,"source":{"system":"sec-edgar","filing":"0001231919-26-000959","document":"form4-08202026_090856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926000959/form4-08202026_090856.xml","form_type":"4"}},{"id":680022,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:57:08.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":1830,"price":0.38,"value":695.4,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35 to $0.41 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":55663,"source":{"system":"sec-edgar","filing":"0001231919-26-000959","document":"form4-08202026_090856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926000959/form4-08202026_090856.xml","form_type":"4"}},{"id":680021,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:57:08.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":45090,"price":0.38,"value":17134.2,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35 to $0.41 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":1411974,"source":{"system":"sec-edgar","filing":"0001231919-26-000959","document":"form4-08202026_090856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926000959/form4-08202026_090856.xml","form_type":"4"}},{"id":689546,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":1,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":2,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":3,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":4,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-08-12T20:13:55.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":1484401,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By 5AM Opportunities II, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Opportunities II, L.P. (\"Opportunities II\"). 5AM Opportunities II (GP), LLC (\"Opportunities II GP\") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the securities held by Opportunities II. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the securities beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1484401},"source":{"system":"sec-edgar","filing":"0001231919-26-000869","document":"form4-08122026_080846.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000123191926000869/form4-08122026_080846.xml","form_type":"4"}},{"id":689545,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":1,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":2,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":3,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":4,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2026-08-12T20:13:55.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":866018,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By 5AM Opportunities II, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Opportunities II, L.P. (\"Opportunities II\"). 5AM Opportunities II (GP), LLC (\"Opportunities II GP\") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the securities held by Opportunities II. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the securities beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":866018},"source":{"system":"sec-edgar","filing":"0001231919-26-000869","document":"form4-08122026_080846.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000123191926000869/form4-08122026_080846.xml","form_type":"4"}},{"id":689544,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":1,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":2,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":3,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":4,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2026-08-12T20:13:55.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":1823238,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1823238},"source":{"system":"sec-edgar","filing":"0001231919-26-000869","document":"form4-08122026_080846.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000123191926000869/form4-08122026_080846.xml","form_type":"4"}},{"id":689543,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":1,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":2,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":3,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":4,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-08-12T20:13:55.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":3152305,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3152305},"source":{"system":"sec-edgar","filing":"0001231919-26-000869","document":"form4-08122026_080846.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000123191926000869/form4-08122026_080846.xml","form_type":"4"}},{"id":689542,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":1,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":2,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":3,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":4,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T20:13:55.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":2350419,"ownership":{"direct":false,"nature":"By 5AM Opportunities II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Opportunities II, L.P. (\"Opportunities II\"). 5AM Opportunities II (GP), LLC (\"Opportunities II GP\") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the securities held by Opportunities II. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the securities beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":2350419,"source":{"system":"sec-edgar","filing":"0001231919-26-000869","document":"form4-08122026_080846.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000123191926000869/form4-08122026_080846.xml","form_type":"4"}},{"id":689541,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":1,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":2,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":3,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":4,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T20:13:55.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":4975543,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":4975543,"source":{"system":"sec-edgar","filing":"0001231919-26-000869","document":"form4-08122026_080846.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000123191926000869/form4-08122026_080846.xml","form_type":"4"}},{"id":691896,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T23:54:40.000Z","date":"2026-08-10","kind":"sale","planned":false,"acquired":false,"shares":92444,"price":7,"value":647108.0,"ownership":{"direct":false,"nature":"By 5AM Ventures V, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.84 to $7.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein."}],"balance_after":2691337,"source":{"system":"sec-edgar","filing":"0001664281-26-000004","document":"form4-08102026_110836.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000166428126000004/form4-08102026_110836.xml","form_type":"4"}},{"id":691895,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T23:54:40.000Z","date":"2026-08-07","kind":"sale","planned":false,"acquired":false,"shares":52317,"price":6.85,"value":358371.45,"ownership":{"direct":false,"nature":"By 5AM Ventures V, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.80 to $7.01 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":2783781,"source":{"system":"sec-edgar","filing":"0001664281-26-000004","document":"form4-08102026_110836.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000166428126000004/form4-08102026_110836.xml","form_type":"4"}},{"id":691894,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T23:54:40.000Z","date":"2026-08-06","kind":"sale","planned":false,"acquired":false,"shares":10494,"price":7,"value":73458.0,"ownership":{"direct":false,"nature":"By 5AM Ventures V, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.90 to $7.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein."}],"balance_after":2836098,"source":{"system":"sec-edgar","filing":"0001664281-26-000004","document":"form4-08102026_110836.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000166428126000004/form4-08102026_110836.xml","form_type":"4"}},{"id":695879,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":5,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":6,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant (Right to Buy)","published_at":"2026-08-05T21:39:33.000Z","date":"2026-08-03","kind":"purchase","planned":false,"acquired":true,"shares":3179558,"price":1.5299,"value":4864405.7842,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, 5AM Ventures VII, L.P. (\"Ventures VII\") shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by Ventures VII, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, 5AM Ventures VII, L.P. (\"Ventures VII\") shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by Ventures VII, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Ventures VII. 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":3179558,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":3179558},"source":{"system":"sec-edgar","filing":"0001231919-26-000829","document":"form4-08052026_090822.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000123191926000829/form4-08052026_090822.xml","form_type":"4"}},{"id":698833,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-03T21:26:41.000Z","date":"2026-07-31","kind":"sale","planned":false,"acquired":false,"shares":1718,"price":6.85,"value":11768.3,"ownership":{"direct":false,"nature":"By 5AM Ventures V, L.P."},"balance_after":2846592,"source":{"system":"sec-edgar","filing":"0001664281-26-000002","document":"form4-08032026_090837.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000166428126000002/form4-08032026_090837.xml","form_type":"4"}},{"id":698832,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-03T21:26:41.000Z","date":"2026-07-30","kind":"sale","planned":false,"acquired":false,"shares":114756,"price":6.93,"value":795259.08,"ownership":{"direct":false,"nature":"By 5AM Ventures V, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.75 to $6.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein."}],"balance_after":2848310,"source":{"system":"sec-edgar","filing":"0001664281-26-000002","document":"form4-08032026_090837.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000166428126000002/form4-08032026_090837.xml","form_type":"4"}},{"id":739830,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T21:34:51.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders."}],"balance_after":19000,"derivative":{"exercise_price":5.97,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001689375-26-000047","document":"wk-form4_1781300088.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937526000047/wk-form4_1781300088.xml","form_type":"4"}},{"id":995782,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-18T21:36:30.000Z","date":"2025-11-14","kind":"sale","planned":false,"acquired":false,"shares":200000,"price":8.8,"value":1760000.0,"ownership":{"direct":false,"nature":"By 5AM Ventures V, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.80 to $9.023 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein."}],"balance_after":2963066,"source":{"system":"sec-edgar","filing":"0001664281-25-000003","document":"form4-11182025_091127.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000166428125000003/form4-11182025_091127.xml","form_type":"4"}},{"id":1040633,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":5,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":6,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T00:12:20.000Z","date":"2025-09-11","kind":"purchase","planned":false,"acquired":true,"shares":2941176,"price":1.53,"value":4499999.28,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":2941176,"source":{"system":"sec-edgar","filing":"0001231919-25-000196","document":"form4-09152025_100930.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000123191925000196/form4-09152025_100930.xml","form_type":"4"}},{"id":1058371,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-22T23:05:36.000Z","date":"2025-08-22","kind":"sale","planned":false,"acquired":false,"shares":6470,"price":3.42,"value":22127.4,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.59 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":57493,"source":{"system":"sec-edgar","filing":"0001415889-25-022806","document":"form4-08222025_110831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000141588925022806/form4-08222025_110831.xml","form_type":"4"}},{"id":1058370,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-22T23:05:36.000Z","date":"2025-08-22","kind":"sale","planned":false,"acquired":false,"shares":163979,"price":3.42,"value":560808.18,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.59 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":1457064,"source":{"system":"sec-edgar","filing":"0001415889-25-022806","document":"form4-08222025_110831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000141588925022806/form4-08222025_110831.xml","form_type":"4"}},{"id":1058369,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-22T23:05:36.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":2314,"price":3.57,"value":8260.98,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.69 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":63963,"source":{"system":"sec-edgar","filing":"0001415889-25-022806","document":"form4-08222025_110831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000141588925022806/form4-08222025_110831.xml","form_type":"4"}},{"id":1058368,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-22T23:05:36.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":58642,"price":3.57,"value":209351.94,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.69 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":1621043,"source":{"system":"sec-edgar","filing":"0001415889-25-022806","document":"form4-08222025_110831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000141588925022806/form4-08222025_110831.xml","form_type":"4"}},{"id":1088600,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-11T21:27:03.000Z","date":"2025-07-09","kind":"sale","planned":false,"acquired":false,"shares":6935,"price":7.502,"value":52026.37,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Kush M. Parmar, M.D., Ph.D. is a managing member of Opportunities GP and may be deemed to share voting and investment power over the shares held by Opportunities. Dr. Parmar disclaims beneficial ownership of the shares held by Opportunities except to the extent of his pecuniary interest therein."}],"balance_after":1093313,"source":{"system":"sec-edgar","filing":"0001415889-25-019680","document":"form4-07112025_090759.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925019680/form4-07112025_090759.xml","form_type":"4"}},{"id":1088599,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-11T21:27:03.000Z","date":"2025-07-09","kind":"sale","planned":false,"acquired":false,"shares":20065,"price":7.502,"value":150527.63,"ownership":{"direct":false,"nature":"By 5AM Ventures V, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein."}],"balance_after":3163066,"source":{"system":"sec-edgar","filing":"0001415889-25-019680","document":"form4-07112025_090759.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925019680/form4-07112025_090759.xml","form_type":"4"}},{"id":1097862,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T00:33:41.000Z","date":"2025-07-01","kind":"sale","planned":false,"acquired":false,"shares":6422,"price":7.1226,"value":45741.3372,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Kush M. Parmar, M.D., Ph.D. is a managing member of Opportunities GP and may be deemed to share voting and investment power over the shares held by Opportunities. Dr. Parmar disclaims beneficial ownership of the shares held by Opportunities except to the extent of his pecuniary interest therein."}],"balance_after":1100248,"source":{"system":"sec-edgar","filing":"0001415889-25-018824","document":"form4-07022025_120738.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925018824/form4-07022025_120738.xml","form_type":"4"}},{"id":1097861,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T00:33:41.000Z","date":"2025-07-01","kind":"sale","planned":false,"acquired":false,"shares":18578,"price":7.1226,"value":132323.6628,"ownership":{"direct":false,"nature":"By 5AM Ventures V, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein."}],"balance_after":3183131,"source":{"system":"sec-edgar","filing":"0001415889-25-018824","document":"form4-07022025_120738.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925018824/form4-07022025_120738.xml","form_type":"4"}},{"id":1097860,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T00:33:41.000Z","date":"2025-06-30","kind":"sale","planned":false,"acquired":false,"shares":6422,"price":6.8127,"value":43751.1594,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Kush M. Parmar, M.D., Ph.D. is a managing member of Opportunities GP and may be deemed to share voting and investment power over the shares held by Opportunities. Dr. Parmar disclaims beneficial ownership of the shares held by Opportunities except to the extent of his pecuniary interest therein."}],"balance_after":1106670,"source":{"system":"sec-edgar","filing":"0001415889-25-018824","document":"form4-07022025_120738.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925018824/form4-07022025_120738.xml","form_type":"4"}},{"id":1097859,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T00:33:41.000Z","date":"2025-06-30","kind":"sale","planned":false,"acquired":false,"shares":18578,"price":6.8127,"value":126566.3406,"ownership":{"direct":false,"nature":"By 5AM Ventures V, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein."}],"balance_after":3201709,"source":{"system":"sec-edgar","filing":"0001415889-25-018824","document":"form4-07022025_120738.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925018824/form4-07022025_120738.xml","form_type":"4"}},{"id":1097858,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T00:33:41.000Z","date":"2025-06-27","kind":"sale","planned":false,"acquired":false,"shares":19265,"price":6.91,"value":133121.15,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Kush M. Parmar, M.D., Ph.D. is a managing member of Opportunities GP and may be deemed to share voting and investment power over the shares held by Opportunities. Dr. Parmar disclaims beneficial ownership of the shares held by Opportunities except to the extent of his pecuniary interest therein."}],"balance_after":1113092,"source":{"system":"sec-edgar","filing":"0001415889-25-018824","document":"form4-07022025_120738.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925018824/form4-07022025_120738.xml","form_type":"4"}},{"id":1097857,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T00:33:41.000Z","date":"2025-06-27","kind":"sale","planned":false,"acquired":false,"shares":55735,"price":6.91,"value":385128.85,"ownership":{"direct":false,"nature":"By 5AM Ventures V, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein."}],"balance_after":3220287,"source":{"system":"sec-edgar","filing":"0001415889-25-018824","document":"form4-07022025_120738.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925018824/form4-07022025_120738.xml","form_type":"4"}},{"id":1113394,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T12:10:21.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 11, 2025 or (ii) the Issuer's next annual meeting of stockholders."}],"balance_after":19000,"derivative":{"exercise_price":7.9,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001689375-25-000034","document":"wk-form4_1749730215.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937525000034/wk-form4_1749730215.xml","form_type":"4"}},{"id":1386765,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-15T21:56:35.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":3395816,"ownership":{"direct":false,"nature":"By 5AM Opportunities II, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly held by 5AM Opportunities II, L.P. (\"Opportunities II\"). 5AM Opportunities II (GP), LLC (\"Opportunities II GP\") is the sole general partner of Opportunities II. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP and Dr. Parmar disclaims beneficial ownership of such shares, except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":302770},"source":{"system":"sec-edgar","filing":"0001415889-24-025140","document":"form4-10152024_091031.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924025140/form4-10152024_091031.xml","form_type":"4"}},{"id":1386764,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-15T21:56:35.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":4244770,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":378463},"source":{"system":"sec-edgar","filing":"0001415889-24-025140","document":"form4-10152024_091031.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924025140/form4-10152024_091031.xml","form_type":"4"}},{"id":1386763,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Prime Preferred Stock","published_at":"2024-10-15T21:56:35.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":15002166,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1337592},"source":{"system":"sec-edgar","filing":"0001415889-24-025140","document":"form4-10152024_091031.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924025140/form4-10152024_091031.xml","form_type":"4"}},{"id":1386762,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T21:56:35.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":909090,"price":11,"value":9999990.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":2625145,"source":{"system":"sec-edgar","filing":"0001415889-24-025140","document":"form4-10152024_091031.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924025140/form4-10152024_091031.xml","form_type":"4"}},{"id":1386761,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T21:56:35.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":302770,"ownership":{"direct":false,"nature":"By 5AM Opportunities II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly held by 5AM Opportunities II, L.P. (\"Opportunities II\"). 5AM Opportunities II (GP), LLC (\"Opportunities II GP\") is the sole general partner of Opportunities II. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP and Dr. Parmar disclaims beneficial ownership of such shares, except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":302770,"source":{"system":"sec-edgar","filing":"0001415889-24-025140","document":"form4-10152024_091031.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924025140/form4-10152024_091031.xml","form_type":"4"}},{"id":1386760,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T21:56:35.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":1716055,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":1716055,"source":{"system":"sec-edgar","filing":"0001415889-24-025140","document":"form4-10152024_091031.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924025140/form4-10152024_091031.xml","form_type":"4"}},{"id":1407809,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T22:54:09.000Z","date":"2024-09-13","kind":"sale","planned":false,"acquired":false,"shares":79,"price":6.06,"value":478.74,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.05 to $6.11 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":66277,"source":{"system":"sec-edgar","filing":"0001415889-24-023399","document":"form4-09132024_100903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000141588924023399/form4-09132024_100903.xml","form_type":"4"}},{"id":1407808,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T22:54:09.000Z","date":"2024-09-13","kind":"sale","planned":false,"acquired":false,"shares":2000,"price":6.06,"value":12120.0,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.05 to $6.11 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":1679685,"source":{"system":"sec-edgar","filing":"0001415889-24-023399","document":"form4-09132024_100903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000141588924023399/form4-09132024_100903.xml","form_type":"4"}},{"id":1407807,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T22:54:09.000Z","date":"2024-09-13","kind":"sale","planned":false,"acquired":false,"shares":11758,"price":6.06,"value":71253.48,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.05 to $6.11 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":8167206,"source":{"system":"sec-edgar","filing":"0001415889-24-023399","document":"form4-09132024_100903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000141588924023399/form4-09132024_100903.xml","form_type":"4"}},{"id":1407806,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T22:54:09.000Z","date":"2024-09-11","kind":"sale","planned":false,"acquired":false,"shares":1440,"price":6.6,"value":9504.0,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":66356,"source":{"system":"sec-edgar","filing":"0001415889-24-023399","document":"form4-09132024_100903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000141588924023399/form4-09132024_100903.xml","form_type":"4"}},{"id":1407805,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T22:54:09.000Z","date":"2024-09-11","kind":"sale","planned":false,"acquired":false,"shares":36504,"price":6.6,"value":240926.4,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":1681685,"source":{"system":"sec-edgar","filing":"0001415889-24-023399","document":"form4-09132024_100903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000141588924023399/form4-09132024_100903.xml","form_type":"4"}},{"id":1407804,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T22:54:09.000Z","date":"2024-09-11","kind":"sale","planned":false,"acquired":false,"shares":214556,"price":6.6,"value":1416069.6,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":8178964,"source":{"system":"sec-edgar","filing":"0001415889-24-023399","document":"form4-09132024_100903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000141588924023399/form4-09132024_100903.xml","form_type":"4"}},{"id":1449434,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-07-24T20:15:09.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":false,"shares":214692,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":214692},"source":{"system":"sec-edgar","filing":"0001415889-24-020035","document":"form4-07242024_040705.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924020035/form4-07242024_040705.xml","form_type":"4"}},{"id":1449433,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2024-07-24T20:15:09.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":false,"shares":843592,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":843592},"source":{"system":"sec-edgar","filing":"0001415889-24-020035","document":"form4-07242024_040705.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924020035/form4-07242024_040705.xml","form_type":"4"}},{"id":1449432,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-24T20:15:09.000Z","date":"2024-07-22","kind":"purchase","planned":false,"acquired":true,"shares":833333,"price":12,"value":9999996.0,"ownership":{"direct":false,"nature":"By 5AM Opportunities II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares are held by 5AM Opportunities II, L.P. (\"Opportunities II\"). 5AM Opportunities II (GP), LLC (\"Opportunities II GP\") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the shares held by Opportunities II.  Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":1182054,"source":{"system":"sec-edgar","filing":"0001415889-24-020035","document":"form4-07242024_040705.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924020035/form4-07242024_040705.xml","form_type":"4"}},{"id":1449431,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-24T20:15:09.000Z","date":"2024-07-22","kind":"other","planned":false,"acquired":true,"shares":348721,"price":10.2,"value":3556954.2,"ownership":{"direct":false,"nature":"By 5AM Opportunities II, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the conversion of outstanding simple agreement for future equity in the amount of $3,556,957.78 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares are held by 5AM Opportunities II, L.P. (\"Opportunities II\"). 5AM Opportunities II (GP), LLC (\"Opportunities II GP\") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the shares held by Opportunities II.  Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":348721,"source":{"system":"sec-edgar","filing":"0001415889-24-020035","document":"form4-07242024_040705.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924020035/form4-07242024_040705.xml","form_type":"4"}},{"id":1449430,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-24T20:15:09.000Z","date":"2024-07-22","kind":"other","planned":false,"acquired":true,"shares":112966,"price":10.2,"value":1152253.2,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the conversion of outstanding simple agreement for future equity in the amount of $1,152,253.93 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":1171250,"source":{"system":"sec-edgar","filing":"0001415889-24-020035","document":"form4-07242024_040705.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924020035/form4-07242024_040705.xml","form_type":"4"}},{"id":1449429,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-24T20:15:09.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":true,"shares":1058284,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":1058284,"source":{"system":"sec-edgar","filing":"0001415889-24-020035","document":"form4-07242024_040705.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924020035/form4-07242024_040705.xml","form_type":"4"}},{"id":1479024,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T20:39:26.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 13, 2024 or (ii) the Issuer's next annual meeting of\nstockholders."}],"balance_after":16000,"derivative":{"exercise_price":16.45,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001689375-24-000038","document":"wk-form4_1718397557.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937524000038/wk-form4_1718397557.xml","form_type":"4"}},{"id":1511524,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2024-05-17T21:05:09.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 15, 2025 or the date of the Company's 2025 Annual Meeting of Stockholders."}],"balance_after":16500,"derivative":{"exercise_price":1.91,"expiration_date":"2034-05-15","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001739410-24-000091","document":"wk-form4_1715979881.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000091/wk-form4_1715979881.xml","form_type":"4"}},{"id":1574964,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-15T20:15:21.000Z","date":"2024-03-13","kind":"purchase","planned":false,"acquired":true,"shares":450000,"price":10,"value":4500000.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":8393520,"source":{"system":"sec-edgar","filing":"0001415889-24-008107","document":"form4-03152024_040305.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000141588924008107/form4-03152024_040305.xml","form_type":"4"}},{"id":1638273,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":3,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":4,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-16T21:15:31.000Z","date":"2024-02-14","kind":"sale","planned":false,"acquired":false,"shares":136642,"price":14.9,"value":2035965.8,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.89 to $14.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares, except to the extent of its or his respective pecuniary interest therein."}],"balance_after":635341,"source":{"system":"sec-edgar","filing":"0001415889-24-004111","document":"form4-02162024_040204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924004111/form4-02162024_040204.xml","form_type":"4"}},{"id":1638272,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":3,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":4,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-16T21:15:31.000Z","date":"2024-02-14","kind":"sale","planned":false,"acquired":false,"shares":688358,"price":14.9,"value":10256534.2,"ownership":{"direct":false,"nature":"By 5AMVentures VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.89 to $14.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":3200634,"source":{"system":"sec-edgar","filing":"0001415889-24-004111","document":"form4-02162024_040204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924004111/form4-02162024_040204.xml","form_type":"4"}},{"id":1662130,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-02T21:32:53.000Z","date":"2024-01-31","kind":"purchase","planned":false,"acquired":true,"shares":5206074,"price":2.31,"value":12026030.94,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":7943520,"source":{"system":"sec-edgar","filing":"0001209191-24-002643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000120919124002643/doc4.xml","form_type":"4"}},{"id":1661737,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":3,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":4,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-02T21:29:43.000Z","date":"2024-01-31","kind":"sale","planned":false,"acquired":false,"shares":82813,"price":15,"value":1242195.0,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares, except to the extent of its or his respective pecuniary interest therein."}],"balance_after":771983,"source":{"system":"sec-edgar","filing":"0001415889-24-002295","document":"form4-02022024_090230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924002295/form4-02022024_090230.xml","form_type":"4"}},{"id":1661736,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":3,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":4,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-02T21:29:43.000Z","date":"2024-01-31","kind":"sale","planned":false,"acquired":false,"shares":417187,"price":15,"value":6257805.0,"ownership":{"direct":false,"nature":"By 5AMVentures VI, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":3888992,"source":{"system":"sec-edgar","filing":"0001415889-24-002295","document":"form4-02022024_090230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924002295/form4-02022024_090230.xml","form_type":"4"}},{"id":1687944,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2024-01-04T22:58:14.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":27118,"price":1.77,"value":47998.86,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $48,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2024."}],"balance_after":27118,"derivative":{"exercise_price":2.4,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":27118},"source":{"system":"sec-edgar","filing":"0001739410-24-000004","document":"wk-form4_1704409080.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000004/wk-form4_1704409080.xml","form_type":"4"}},{"id":1772143,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":3,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":4,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-28T20:27:26.000Z","date":"2023-09-26","kind":"sale","planned":false,"acquired":false,"shares":32711,"price":15,"value":490665.0,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares, except to the extent of its or his respective pecuniary interest therein."}],"balance_after":854796,"source":{"system":"sec-edgar","filing":"0001209191-23-050731","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123050731/doc4.xml","form_type":"4"}},{"id":1772142,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":3,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":4,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-28T20:27:26.000Z","date":"2023-09-26","kind":"sale","planned":false,"acquired":false,"shares":164789,"price":15,"value":2471835.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":4306179,"source":{"system":"sec-edgar","filing":"0001209191-23-050731","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123050731/doc4.xml","form_type":"4"}},{"id":1795317,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":3,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":4,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-28T20:20:16.000Z","date":"2023-08-24","kind":"sale","planned":false,"acquired":false,"shares":72876,"price":16,"value":1166016.0,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares, except to the extent of its or his respective pecuniary interest therein."}],"balance_after":887507,"source":{"system":"sec-edgar","filing":"0001209191-23-047514","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123047514/doc4.xml","form_type":"4"}},{"id":1795316,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":3,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":4,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-28T20:20:16.000Z","date":"2023-08-24","kind":"sale","planned":false,"acquired":false,"shares":367124,"price":16,"value":5873984.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":4470968,"source":{"system":"sec-edgar","filing":"0001209191-23-047514","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123047514/doc4.xml","form_type":"4"}},{"id":1858826,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-12T20:06:35.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 8, 2023 (the \"Vesting Start Date\") or (ii) the Issuer's next annual meeting of stockholders."}],"balance_after":16000,"derivative":{"exercise_price":14.67,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-23-070338","document":"tm2318445-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000110465923070338/tm2318445-4_4seq1.xml","form_type":"4"}},{"id":1884739,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2023-05-19T21:26:16.000Z","date":"2023-05-17","kind":"grant","planned":false,"acquired":true,"shares":15490,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted under the Company's 2021 Equity Incentive Plan.  The option vests on the earlier of May 17, 2024 or the date of the Company's 2024 Annual Meeting of Stockholders."}],"balance_after":15490,"derivative":{"exercise_price":5.64,"expiration_date":"2033-05-17","underlying":"Common Stock","underlying_shares":15490},"source":{"system":"sec-edgar","filing":"0000899243-23-013407","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924323013407/doc4.xml","form_type":"4"}},{"id":1961139,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-09T21:39:25.000Z","date":"2023-03-07","kind":"sale","acquired":false,"shares":100000,"price":8.2,"value":820000.0,"ownership":{"direct":false,"nature":"By 5AM Ventures V, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held directly by 5AM Ventures V, L.P. (\"Ventures V\"). 5AM Partners V, LLC (\"Partners V\") is the sole general partner of Ventures V. Dr. Parmar is a managing member of Partners V and may be deemed to share voting and investment power over the securities held by Ventures V. Dr. Parmar disclaims beneficial ownership of the securities held by Ventures V except to the extent of his pecuniary interest therein."}],"balance_after":2378969,"source":{"system":"sec-edgar","filing":"0001209191-23-017538","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000120919123017538/doc4.xml","form_type":"4"}},{"id":1987482,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":4,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":6,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":7,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":8,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-28T21:29:55.000Z","date":"2023-02-24","kind":"other","acquired":false,"shares":496323,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (2)]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from footnote (1)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (2)]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[continues from footnote (1)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares are held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Mr. Schwab and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-013671","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000120919123013671/doc4.xml","form_type":"4"}},{"id":1987481,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":4,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":6,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":7,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":8,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-28T21:29:55.000Z","date":"2023-02-24","kind":"other","acquired":false,"shares":487333,"ownership":{"direct":false,"nature":"By 5AM Opportunities II, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (2)]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from footnote (1)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (2)]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[continues from footnote (1)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares are held by 5AM Opportunities II, L.P. (\"Opportunities II\"). 5AM Opportunities II (GP), LLC (\"Opportunities II GP\") is the sole general partner of Opportunities II. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP, Mr. Schwab and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-013671","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000120919123013671/doc4.xml","form_type":"4"}},{"id":1987480,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":4,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":6,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":7,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":8,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-28T21:29:55.000Z","date":"2023-02-24","kind":"other","acquired":false,"shares":3953990,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (2)]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from footnote (1)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (2)]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[continues from footnote (1)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-013671","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000120919123013671/doc4.xml","form_type":"4"}},{"id":2062867,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2023-01-05T23:29:31.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":10344,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2023."}],"balance_after":10344,"derivative":{"exercise_price":6.19,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":10344},"source":{"system":"sec-edgar","filing":"0000899243-23-001048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924323001048/doc4.xml","form_type":"4"}},{"id":2098375,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-12-02T16:49:13.000Z","date":"2022-12-01","kind":"disposition_to_issuer","acquired":false,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the effective time of the merger (the \"Effective Time\"), pursuant to the Merger Agreement, each outstanding option to purchase Shares having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by (B) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option and (y) one CVR for each Share subject to such option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"At the effective time of the merger (the \"Effective Time\"), pursuant to the Merger Agreement, each outstanding option to purchase Shares having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by (B) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option and (y) one CVR for each Share subject to such option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":4.21,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-22-124136","document":"tm2231851-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465922124136/tm2231851-3_4seq1.xml","form_type":"4"}},{"id":2098374,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-02T16:49:13.000Z","date":"2022-11-30","kind":"other","acquired":false,"shares":982453,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Kearny Acquisition Corporation (\"Merger Sub\"), dated as of October 17, 2022, these shares of common stock, par value $0.0001 per share, of the Issuer (\"Shares\") were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for (i) $12.50 per Share, net to the stockholder in cash, without interest (the \"Cash Consideration\") and less any applicable tax withholding, plus [Continued on Note 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[Continuation of Note 1] (ii) one non-tradable contingent value right (\"CVR\") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Kearny Acquisition Corporation (\"Merger Sub\"), dated as of October 17, 2022, these shares of common stock, par value $0.0001 per share, of the Issuer (\"Shares\") were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for (i) $12.50 per Share, net to the stockholder in cash, without interest (the \"Cash Consideration\") and less any applicable tax withholding, plus [Continued on Note 2]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[Continuation of Note 1] (ii) one non-tradable contingent value right (\"CVR\") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares were held directly by 5AM Opportunities I, L.P. (\"Opportunities I\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the general partner of Opportunities I and may be deemed to have sole investment and voting power over the Shares held by Opportunities I. The Reporting Person is a Managing Member of Opportunities GP and may be deemed to have shared voting and dispositive power over the Shares held by Opportunities I. Therefore, the Reporting Person may be deemed to have beneficially owned the Shares held by Opportunities I. The Reporting Person disclaims beneficial ownership over the Shares held by Opportunities I except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-22-124136","document":"tm2231851-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465922124136/tm2231851-3_4seq1.xml","form_type":"4"}},{"id":2098373,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-02T16:49:13.000Z","date":"2022-11-30","kind":"other","acquired":false,"shares":3153333,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Kearny Acquisition Corporation (\"Merger Sub\"), dated as of October 17, 2022, these shares of common stock, par value $0.0001 per share, of the Issuer (\"Shares\") were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for (i) $12.50 per Share, net to the stockholder in cash, without interest (the \"Cash Consideration\") and less any applicable tax withholding, plus [Continued on Note 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[Continuation of Note 1] (ii) one non-tradable contingent value right (\"CVR\") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Kearny Acquisition Corporation (\"Merger Sub\"), dated as of October 17, 2022, these shares of common stock, par value $0.0001 per share, of the Issuer (\"Shares\") were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for (i) $12.50 per Share, net to the stockholder in cash, without interest (the \"Cash Consideration\") and less any applicable tax withholding, plus [Continued on Note 2]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[Continuation of Note 1] (ii) one non-tradable contingent value right (\"CVR\") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares were held directly by 5AM Ventures V, L.P. (\"Ventures V\"). 5AM Partners V, LLC (\"Partners V\") is the general partner of Ventures V and may be deemed to have sole investment and voting power over the Shares held by Ventures V. The Reporting Person is a Managing Member of Partners V and may be deemed to have shared voting and dispositive power over the Shares held by Ventures V. Therefore, the Reporting Person may be deemed to have beneficially owned the Shares held by Ventures V. The Reporting Person disclaims beneficial ownership over the Shares held by Ventures V except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-22-124136","document":"tm2231851-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465922124136/tm2231851-3_4seq1.xml","form_type":"4"}},{"id":2182203,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":3,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":4,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":5,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":6,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":7,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":8,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-18T00:01:34.000Z","date":"2022-08-15","kind":"purchase","acquired":true,"shares":487333,"price":30,"value":14619990.0,"ownership":{"direct":false,"nature":"By 5AM Opportunities II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by 5AM Opportunities II, L.P. (\"Opportunities II\"). 5AM Opportunities II (GP), LLC (\"Opportunities II GP\") is the sole general partner of Opportunities II. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP, Mr. Schwab and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein."}],"balance_after":487333,"source":{"system":"sec-edgar","filing":"0001209191-22-046494","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000120919122046494/doc4.xml","form_type":"4"}},{"id":2182202,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":3,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":4,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":5,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":6,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":7,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":8,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-18T00:01:34.000Z","date":"2022-08-15","kind":"purchase","acquired":true,"shares":112667,"price":30,"value":3380010.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein."}],"balance_after":3953990,"source":{"system":"sec-edgar","filing":"0001209191-22-046494","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000120919122046494/doc4.xml","form_type":"4"}},{"id":2221174,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-27T17:02:19.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 23, 2022. The shares underlying the option will fully vest on the earlier of (i) June 23, 2023 and (ii) the date of the Issuer's 2023 annual meeting of stockholders."}],"balance_after":16000,"derivative":{"exercise_price":4.21,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-22-074826","document":"tm2219359-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465922074826/tm2219359-1_4seq1.xml","form_type":"4"}},{"id":2226532,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2022-06-17T20:05:20.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable on the earlier of June 15, 2023 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":18000,"derivative":{"exercise_price":1.88,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000899243-22-023063","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661998/000089924322023063/doc4.xml","form_type":"4"}},{"id":2230134,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-16T21:09:59.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":16911,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":16911,"derivative":{"exercise_price":4.26,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":16911},"source":{"system":"sec-edgar","filing":"0001209191-22-037516","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000120919122037516/doc4.xml","form_type":"4"}},{"id":2240289,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-07T21:03:56.000Z","date":"2022-06-03","kind":"sale","acquired":false,"shares":50329,"price":12.5,"value":629112.5,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by 5AM Opportunities I, L.P. (\"Opportunities I, L.P.\"). 5AM Opportunities I (GP), LLC (\"Opportunities I (GP)\") is the general partner of Opportunities I, L.P. Dr. Parmar is a managing member of Opportunities I (GP), and may be deemed to share voting and dispositive power over the securities held by Opportunities I, L.P. Dr. Parmar disclaims beneficial ownership of the securities held by Opportunities I, L.P. except to the extent of his pecuniary interest therein."}],"balance_after":1251755,"source":{"system":"sec-edgar","filing":"0001209191-22-034860","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000120919122034860/doc4.xml","form_type":"4"}},{"id":2240288,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-07T21:03:56.000Z","date":"2022-06-03","kind":"sale","acquired":false,"shares":99671,"price":12.5,"value":1245887.5,"ownership":{"direct":false,"nature":"By 5AM Ventures V, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held directly by 5AM Ventures V, L.P. (\"Ventures V\"). 5AM Partners V, LLC (\"Partners V\") is the sole general partner of Ventures V. Dr. Parmar is a managing member of Partners V and may be deemed to share voting and investment power over the securities held by Ventures V. Dr. Parmar disclaims beneficial ownership of the securities held by Ventures V except to the extent of his pecuniary interest therein."}],"balance_after":2478969,"source":{"system":"sec-edgar","filing":"0001209191-22-034860","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000120919122034860/doc4.xml","form_type":"4"}},{"id":2242399,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-06T20:01:55.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":11918,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 2, 2022 (the \"Vesting Start Date\") or (ii) the Issuer's next annual meeting of stockholders."}],"balance_after":11918,"derivative":{"exercise_price":6.06,"expiration_date":"2032-06-02","underlying":"Common Stock","underlying_shares":11918},"source":{"system":"sec-edgar","filing":"0001104659-22-068502","document":"tm2217670-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000110465922068502/tm2217670-3_4seq1.xml","form_type":"4"}},{"id":2255343,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2022-05-27T00:08:32.000Z","date":"2022-05-24","kind":"grant","acquired":true,"shares":13440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted under the Company's 2021 Equity Incentive Plan.  The option vests on the earlier of May 24, 2023 or the date of the Company's 2023 Annual Meeting of Stockholders."}],"balance_after":13440,"derivative":{"exercise_price":12.75,"expiration_date":"2032-05-24","underlying":"Common Stock","underlying_shares":13440},"source":{"system":"sec-edgar","filing":"0000899243-22-019827","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322019827/doc4.xml","form_type":"4"}},{"id":2256846,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-25T22:34:49.000Z","date":"2022-05-23","kind":"sale","acquired":false,"shares":33553,"price":13,"value":436189.0,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by 5AM Opportunities I, L.P. (\"Opportunities I, L.P.\"). 5AM Opportunities I (GP), LLC (\"Opportunities I (GP)\") is the general partner of Opportunities I, L.P. Dr. Parmar is a managing member of Opportunities I (GP), and may be deemed to share voting and dispositive power over the securities held by Opportunities I, L.P. Dr. Parmar disclaims beneficial ownership of the securities held by Opportunities I, L.P. except to the extent of his pecuniary interest therein."}],"balance_after":1302084,"source":{"system":"sec-edgar","filing":"0001209191-22-031969","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000120919122031969/doc4.xml","form_type":"4"}},{"id":2256845,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-25T22:34:49.000Z","date":"2022-05-23","kind":"sale","acquired":false,"shares":66447,"price":13,"value":863811.0,"ownership":{"direct":false,"nature":"By 5AM Ventures V, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held directly by 5AM Ventures V, L.P. (\"Ventures V\"). 5AM Partners V, LLC (\"Partners V\") is the sole general partner of Ventures V. Dr. Parmar is a managing member of Partners V and may be deemed to share voting and investment power over the securities held by Ventures V. Dr. Parmar disclaims beneficial ownership of the securities held by Ventures V except to the extent of his pecuniary interest therein."}],"balance_after":2578640,"source":{"system":"sec-edgar","filing":"0001209191-22-031969","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000120919122031969/doc4.xml","form_type":"4"}},{"id":2404448,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-10T23:22:43.000Z","date":"2022-02-08","kind":"sale","acquired":false,"shares":70461,"price":13.05,"value":919516.05,"ownership":{"direct":false,"nature":"5AM Opportunities I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by 5AM Opportunities I, L.P. (\"Opportunities I, L.P.\"). 5AM Opportunities I (GP), LLC (\"Opportunities I (GP)\") is the general partner of Opportunities I, L.P. Dr. Parmar is a managing member of Opportunities I (GP), and may be deemed to share voting and dispositive power over the securities held by Opportunities I, L.P. Dr. Parmar disclaims beneficial ownership of the securities held by Opportunities I, L.P. except to the extent of his pecuniary interest therein."}],"balance_after":1335637,"source":{"system":"sec-edgar","filing":"0001209191-22-008579","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000120919122008579/doc4.xml","form_type":"4"}},{"id":2404447,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-10T23:22:43.000Z","date":"2022-02-08","kind":"sale","acquired":false,"shares":139539,"price":13.05,"value":1820983.95,"ownership":{"direct":false,"nature":"5AM Ventures V, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held directly by 5AM Ventures V, L.P. (\"Ventures V\"). 5AM Partners V, LLC (\"Partners V\") is the sole general partner of Ventures V. Dr. Parmar is a managing member of Partners V and may be deemed to share voting and investment power over the securities held by Ventures V. Dr. Parmar disclaims beneficial ownership of the securities held by Ventures V except to the extent of his pecuniary interest therein."}],"balance_after":2645087,"source":{"system":"sec-edgar","filing":"0001209191-22-008579","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000120919122008579/doc4.xml","form_type":"4"}},{"id":2435673,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":3,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":4,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":5,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":6,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2022-01-13T21:45:33.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":625000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Mr. Schwab and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":183823},"source":{"system":"sec-edgar","filing":"0001209191-22-003205","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000120919122003205/doc4.xml","form_type":"4"}},{"id":2435672,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":3,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":4,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":5,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":6,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2022-01-13T21:45:33.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":2525000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":742647},"source":{"system":"sec-edgar","filing":"0001209191-22-003205","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000120919122003205/doc4.xml","form_type":"4"}},{"id":2435671,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":3,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":4,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":5,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":6,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2022-01-13T21:45:33.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":9999999,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2941176},"source":{"system":"sec-edgar","filing":"0001209191-22-003205","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000120919122003205/doc4.xml","form_type":"4"}}],"next_cursor":"2022-01-13T21:45:33.000000Z,2435671"}